ADC Development Services Targeting CA6

Creative Biolabs is a leading expert in the conjugation of highly active molecules to monoclonal antibodies (mAbs) for the development and manufacture of antibody-drug conjugates (ADCs). Creative Biolabs provides world-class expertise in conjugation approaches and can handle highly potent and toxic payloads. Extensive payload and linker libraries as well as mAb libraries is available for your ADCs development. Creative Biolabs provides a full-range of anti-CA6 antigen ADC development and manufacturing services both as an integrated package and standalone services for our worldwide clients. The off-the-shelf Anti-CA6 ADC Product is also available for you.

Introduction of CA6

CA6, carbonic anhydrase 6, is a neuraminidase-sensitive and periodic acidsensitive sialic acid glycoconjugate (“sialoglycotope”). CA6 has limited distribution in normal adult tissues but is often overexpressed in carcinomas of the pancreas, breast, ovary, and bladder. CA6 may play a role in the reversible hydratation of carbon dioxide. Studies have revealed that the CA6 epitope is expressed on an 80 kDa non-disulfide-linked glycoprotein containing N-linked oligosaccharides. Two-dimensional non-equilibrium pH gradient gel electrophoresis indicates an isoelectric point of approximately 6.2 to 6.5.

Anti-CA6 ADC Therapy in Breast Cancer, Ovarian Cancer, Cervical Cancer

Recently, CA6 antigen has been regarded as a promising ADC target for CA6 positive tumors, such as breast cancer, ovarian cancer and cervical cancer. For instance, SAR566658 is an ADC that consists of a humanized mAb against CA6, conjugated to the cytotoxic maytansinoid derivative DM4, with potential antineoplastic activity. The anti-CA6 mAb moiety of SAR566658 targets and binds to the cell surface antigen CA6. Upon antibody/antigen binding and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in inhibition of cell division and cell growth of CA6-expressing tumor cells. SAR566658 is currently undergoing phase I clinical trials in patients who have received a diagnosis of CA6-positive tumors.

Fig.1 Structure of SAR566658. (Trail, 2018)

What Can We Do for You?

ADCs are particularly effective because they exhibit selective cytotoxicity by targeting tumor cells. Creative Biolabs, along with our collaborators, offers comprehensive and coordinated services for the development, manufacture, and testing of ADCs. Creative Biolabs has years of experience in the production and testing of mAbs, giving us the ability to provide complete testing for the bulk mAb and ADC products. In addition, we offer a whole suite of services needed for ADC development, which include:

• ADC Antibody Screening
• Antibody Design and Conjugation
• Linkers and cytotoxic agents produced by our DrugLnk™ Custom Synthesis platform
• Analytical method development and validation, ADC in vitro Analysis and ADC in vivo Analysis

Technology Expertise

We have the right experience and expertise to support your ADC project:

• Development experience with different ADC constructs
• Random cysteine or lysine conjugation technology
• Site directed conjugation via engineered mAbs or enzyme catalyzed
• Various payloads and linker-payload products
• Extensive analytical capabilities for characterization
• Personnel and suites dedicated to ADC development, manufacturing, and testing

Together, Creative Biolabs provide a one-stop shop to meet all your ADC development needs. If you are looking for anti-CA6 ADC development services, Creative Biolabs will be your best choice. Please feel free to contact us for more information.

Reference

1. Trail, P. A.;et al. Antibody drug conjugates for treatment of breast cancer: novel targets and diverse approaches in ADC design. Pharmacology & therapeutics. 2018, 181: 126-142.

For Research Use Only. NOT FOR CLINICAL USE.